These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21968944)

  • 1. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
    Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
    J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma.
    Toffolatti L; Scquizzato E; Cavallin S; Canal F; Scarpa M; Stefani PM; Gherlinzoni F; Dei Tos AP
    Virchows Arch; 2014 Nov; 465(5):579-86. PubMed ID: 25031012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.
    Makino K; Nakamura H; Hide T; Kuratsu J
    J Neurooncol; 2012 Jan; 106(1):155-60. PubMed ID: 21720808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.
    Esteller M; Gaidano G; Goodman SN; Zagonel V; Capello D; Botto B; Rossi D; Gloghini A; Vitolo U; Carbone A; Baylin SB; Herman JG
    J Natl Cancer Inst; 2002 Jan; 94(1):26-32. PubMed ID: 11773279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R
    N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
    Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
    Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
    Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
    BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
    Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Hertzman Johansson C; Lindén D; Johansson H; Frostvik Stolt M; Walker C; Snowden H; Newton-Bishop J; Hansson J; Egyházi Brage S
    Int J Cancer; 2015 Jun; 136(12):2844-53. PubMed ID: 25400033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status.
    Kurzwelly D; Glas M; Roth P; Weimann E; Lohner H; Waha A; Schabet M; Reifenberger G; Weller M; Herrlinger U
    J Neurooncol; 2010 May; 97(3):389-92. PubMed ID: 19841864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
    Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
    Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
    Jiang X; Reardon DA; Desjardins A; Vredenburgh JJ; Quinn JA; Austin AD; Herndon JE; McLendon RE; Friedman HS
    J Neurooncol; 2013 Aug; 114(1):135-40. PubMed ID: 23686298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
    Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
    Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
    Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
    J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
    Taal W; Dubbink HJ; Zonnenberg CB; Zonnenberg BA; Postma TJ; Gijtenbeek JM; Boogerd W; Groenendijk FH; Kros JM; Kouwenhoven MC; van Marion R; van Heuvel I; van der Holt B; Bromberg JE; Sillevis Smitt PA; Dinjens WN; van den Bent MJ;
    Neuro Oncol; 2011 Feb; 13(2):235-41. PubMed ID: 21177338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.